Date published: 2026-4-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

CETP Activators

Cholesteryl ester transfer protein (CETP) is an integral plasma protein involved in the regulation of lipid metabolism, specifically facilitating the transfer of cholesteryl esters and triglycerides between different lipoproteins. Its primary action is to mediate the exchange of cholesteryl esters from high-density lipoproteins (HDL) to apolipoprotein B-containing lipoproteins, like low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). As a result, CETP plays a pivotal role in determining the levels and distribution of cholesterol and other lipids in the bloodstream.

CETP activators are compounds that enhance the activity of the CETP protein. By amplifying CETP's natural function, these activators can influence the equilibrium of lipid particles in the plasma. Such modulations can lead to alterations in the lipid profile, influencing the size and number of HDL and LDL particles. The mechanism of action of CETP activators is often rooted in their ability to bind directly or indirectly to the CETP protein, leading to an increased transfer rate of cholesteryl esters and triglycerides between lipoproteins. The structure and chemical nature of CETP activators can vary, but their unifying feature is their impact on the CETP-mediated lipid exchange process. As with any class of compounds influencing a complex biological process, understanding the precise molecular interactions and consequences of CETP activation remains a topic of extensive scientific investigation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dalcetrapib

211513-37-0sc-364479
sc-364479A
10 mg
50 mg
$720.00
$1900.00
(0)

Another CETP inhibitor aimed at elevating HDL cholesterol. it did increase HDL levels but did not reduce the risk of cardiovascular events.

Anacetrapib

875446-37-0sc-364404
sc-364404A
10 mg
50 mg
$615.00
$1785.00
(0)

Anacetrapib is another CETP inhibitor that showed efficacy in raising HDL cholesterol and decreasing LDL cholesterol. Late-stage trials showed some cardiovascular benefits, but its commercial development was not pursued.